Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All provided claims are consistent with the FDA label excerpt that APIDRA is insulin glulisine, but manufacturing/brand/marketer (Sanofi) is not supported or contradicted by the supplied prescribing information excerpts.
Category Scores
Accurate Statements
Apidra’s active ingredient is insulin glulisine.
The label excerpt identifies APIDRA as insulin glulisine (e.g., APIDRA is referred to as insulin glulisine in contraindications, warnings, and clinical/excerpted material).
Unsupported Statements
Apidra is manufactured by Sanofi.
The provided label excerpts do not state the manufacturer or manufacturing company.
In the U.S., Apidra (insulin glulisine injection) is marketed under Sanofi’s brand name.
The provided label excerpts do not state the marketer/brand ownership in the U.S.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The only label-supported claim is about the active ingredient. Unsupported claims about manufacturing/marketing are not prescribing-safety relevant based on the supplied excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Company/manufacturer/marketing attribution (Sanofi) is not supported by the provided prescribing information excerpts.
Suggested Improvement
Remove or qualify Sanofi/manufacturing/marketing statements unless citing label sections not included in the provided excerpts (e.g., manufacturer/marketing authorization holder).